<DOC>
	<DOCNO>NCT00646269</DOCNO>
	<brief_summary>ETNA3 multicentric randomise clinical trial conduct France evaluate impact cognitive training , reminiscence therapy `` made-to-measure '' program progression rate dementia .</brief_summary>
	<brief_title>Efficacy Assessment Three Non Pharmacological Therapies Alzheimer 's Disease</brief_title>
	<detailed_description>ETNA3 multicentric randomise clinical trial conduct France evaluate impact non pharmacological treatment progression rate dementia : Three non pharmacological treatment study : cognitive training therapy , reminiscence therapy `` made-to-measure '' program . Nearly 40 `` Memory Clinics '' participate . 800 patient suffer Alzheimer 's Disease mild moderate stage disease include . For therapy , standard intervention protocol define . The main objective determine whether several non pharmacological treatment delay severe stage dementia 2-year follow-up . The secondary outcome assess cognitive ability , functional ability activity daily live , behavioural disturbance , apathy , quality life , depression , caregiver burden resource utilization</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients mild moderate stage Alzheimer 's Disease : MMSE score 16 26 ; stage 3 5 Global Deterioration Scale Patients 50 year age Patients social security affiliation Patients suffer type dementia Institutionalized patient Patients psychiatric disorder Patients severe pathology terminal stage Patients receive non pharmacological therapy propose study Enrollment pharmacological trial first 6 month</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Dementia ; Alzheimer 's Disease ; Non pharmacological treatment ; cognitive training ; reminiscence therapy ; efficacy assessment</keyword>
</DOC>